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REVIEW
Abstract: Tumor necrosis factor (TNF) has been implicated in a number of arthritic disease
states, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Adalimumab is the first fully human, high-affinity, recombinant immunoglobulin G1 (IgG1)
anti-TNF monoclonal antibody. Adalimumab in combination with methotrexate or standard
antirheumatic therapies, or as monotherapy, is effective in the treatment of adults with active
rheumatoid arthritis who have had an inadequate response to disease-modifying antirheumatic
drugs. Adalimumab is also effective in the treatment of patients with moderately to severely
active psoriatic arthritis, improving both joint and skin manifestations of the disease as well
as disability due to joint damage. In the Adalimumab Trial Evaluating Long-term Efficacy
and Safety in Ankylosing Spondylitis (ATLAS), adalimumab significantly reduced the signs
and symptoms of active ankylosing spondylitis and established a sustained clinical response
in patients who had an inadequate response or intolerance to nonsteroidal antiinflammatory
drug therapy. Overall, across these indications, adalimumab demonstrated a rapid onset of
action, sustained efficacy with long-term treatment, and was well-tolerated, with few patients
discontinuing treatment because of adverse events. The safety profile was similar to other
TNF antagonists. Inhibition of TNF activity by adalimumab also significantly improved
physical functioning and quality of life measures.
Keywords: Adalimumab, TNF antagonists, rheumatoid arthritis, psoriatic arthritis, ankylosing
spondylitis
Introduction
Therapeutic options for the treatment of arthritic diseases, including rheumatoid
arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), have been
broadened by the development of specifically targeted biologic agents. Among these
are strategies aimed at specific neutralization of the proinflammatory cytokine tumor
necrosis factor (TNF). The basis for focusing on TNF as a therapeutic target comes
largely from studies showing that concentrations of TNF are elevated in synovial
fluid and sera of patients with active RA (Saxne et al 1988), joints and skin of PsA
patients (Partsch et al 1997; Ritchlin et al 1998), and sacroiliac joint biopsy specimens
from patients with AS (Braun et al 1995). Three TNF antagonists are currently
available (Lee and Kavanaugh 2005) (Figure 1): infliximab, a chimeric monoclonal
anti-TNF antibody; etanercept, a recombinant soluble p75 TNF-receptor-Fc fusion
protein; and adalimumab, a human monoclonal anti-TNF antibody. All 3 agents have
demonstrated efficacy in the treatment of RA; however, efficacy in other inflammatory
arthritides varies because of differences in drug characteristics (eg, pharmacokinetics,
dosing, immunogenicity, ability to block lymphotoxin or fix complement, or
propensity to induce apoptosis) and disease pathophysiology (eg, role of lymphotoxin)
(Haraoui 2005). This review will focus specifically on the clinical efficacy and safety
of adalimumab in RA, PsA, and AS.
Adalimumab
Adalimumab is the first fully human, high-affinity, recombinant immunoglobulin G1
(IgG1) anti-TNF monoclonal antibody. It is composed of human-derived heavy- and
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light-chain variable regions and human IgG1:κ constant
regions engineered through phage display technology and
produced in a Chinese hamster ovary mammalian cell line
(van de Putte et al 2003). Because it is indistinguishable in
structure and function from naturally occurring human IgG1,
adalimumab has high selectivity and affinity for TNF;
suitability for long-term chronic administration with a low
degree of immunogenicity, with or without concomitant
methotrexate (MTX) use; a low incidence of allergic
reactions; and a half-life comparable to that of IgG1,
allowing every-other-week dosing for patient convenience.
Adalimumab is currently indicated for reducing the signs
and symptoms, inducing major clinical response, inhibiting
the progression of joint damage, and improving physical
function in adult patients with moderately to severely active
RA, as well as for reducing the signs and symptoms of active
arthritis in patients with PsA. At this time, the manufacturer
of adalimumab has submitted a supplemental Biologics
License Application with the US Food and Drug
Administration and a Type II Variation to the European
Medicines Agency (EMEA) seeking an indication for the
treatment of AS (AL 2005). The Committee for Medicinal
Products for Human Use, the scientific committee of the
EMEA, granted a positive opinion recommending approval
of adalimumab for the treatment of severe active AS based
on results from recent trials.
Figure 1 Adalimumab structure in comparison with other TNF antagonists. Copyright © 2005. Adapted from Anderson PJ. 2005. Tumor necrosis factor inhibitors:
clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum, 34(5 Suppl 1):19–22.
Abbreviations: IgG1, immunoglobulin G1; TNF, tumor necrosis factor.
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Adalimumab exerts its therapeutic effects by blocking
the interaction of TNF with the p55 and p75 cell surface
TNF receptors. It does not bind to other cytokines, such as
lymphotoxin, and interleukins (IL), such as IL-1 (van de
Putte et al 2003; Humira
® PC 2005; Humira PI 2005). TNF
is a potent osteogenic cytokine and the central mediator of
inflammation and joint destruction underlying RA, PsA, and
AS pathology. Produced in the setting of inflammation, TNF
induces receptor activator of NF-κB ligand (RANKL)
expression on the surface of stromal/osteoblast cells
(Thomson et al 1987). Clinical studies have shown that in
patients with RA, TNF blockade is able to attenuate cartilage
and bone destruction (Lipsky et al 2000a; Klareskog et al
2004). This may be attributed in part to the downregulation
of serum matrix metalloproteinase (MMP)-1 and MMP-3
following anti-TNF therapy, as well as downregulating the
role of TNF in osteoclast maturation and activation (Brennan
et al 1997; Catrina et al 2002, 2006).
Pharmacodynamics
In patients with active RA, adalimumab has the following
pharmacodynamic effects:
• Acute-phase reactants of inflammation (C-reactive
protein, fibrinogen, and erythrocyte sedimentation rate)
are rapidly decreased (Humira PI 2005).
• Serum concentrations of IL-1, IL-6, IL-8, and
granulocyte-macrophage colony-stimulating factor are
reduced (Choy and Panayi 2001).
• Systemic concentrations of IL-1β messenger RNA, IL-
1 receptor antagonist, and IL-6 are decreased within 24
hours and remain below baseline concentrations through
Day 14 (Barrera et al 2001).
• Significant reductions from baseline in concentrations
of MMP-1, MMP-3, pro-MMP-1, and pro-MMP-3 and
other markers of cartilage and synovium turnover occur
(eg, oligomeric matrix protein, intracellular adhesion
molecule-1 [ICAM-1], human cartilage glycoprotein-39)
(den Broeder et al 2002; Weinblatt et al 2003).
• Concentrations of adhesion molecules responsible for
leukocyte migration (endothelial-leukocyte adhesion
molecule-1, vascular cell adhesion molecule-1, and
ICAM-1) are reduced (den Broeder et al 2002; Humira
PI 2005).
Importantly, normal immune function is preserved during
adalimumab therapy (Kavanaugh et al 2002).
Pharmacokinetics
The key pharmacokinetic properties of adalimumab are
summarized in Table 1. Linear pharmacokinetics are
observed throughout the clinical dosage range, with the
mean plasma concentration increasing proportionally with
an increase in dosage. In healthy adults, the average
bioavailability of adalimumab was 64% following a single
40 mg subcutaneous (sc) dose, and maximum plasma
concentrations (4.7 µg/mL) were achieved within 5 days.
In 5 patients with RA, adalimumab concentrations in the
synovial fluid were 31% to 96% of those in sera.
Concomitant MTX administration does not adversely affect
adalimumab serum concentrations; adalimumab had an
average steady-state serum concentration of 5mg/mL and
8–9 µg/mL without and with MTX, respectively.
Pharmacokinetic data are not available in patients with
hepatic or renal impairment (Humira PI 2005).
Therapeutic efficacy
Rheumatoid arthritis
Although there are no studies that directly compare
etanercept, infliximab, or adalimumab, data from
noncomparative trials suggest that all 3 agents have similar
therapeutic efficacy in RA. Etanercept has demonstrated
consistent responses in 5 clinical trials, 3 that studied
etanercept monotherapy and 2 that studied combination
etanercept/MTX therapy for periods of up to 26 weeks
(Moreland et al 1997; 1999; Weinblatt et al 1999; Klareskog
et al 2004). The efficacy of infliximab in combination with
MTX in RA was established in 1 large clinical trial (the
Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis
with Concomitant Therapy [ATTRACT] study) (Maini et
al 1999; Lipsky et al 2000a; 2000b). This review will focus
Table 1 Pharmacokinetic properties of adalimumab (Humira PI
2005)
Absolute bioavailability 64%
Time to maximum concentration
a 131 ± 56 h
Maximum serum concentrationa 4.7 ± 1.6 µg/mL
Volume of distribution  4.7–6.0 L
Steady-state trough concentration: 
Without concomitant MTX ~ 5 µg/mL
With concomitant MTX ~ 8–9 µg/mL
Systemic clearance 12 mL/h
Terminal half-life ~ 2 weeks
Note: 
aFollowing a single 40 mg subcutaneous dose.
Abbreviations: MTX, methotrexate.Therapuetics and Clinical Risk Management 2007:3(1) 136
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Table 2 Summary of primary and selected secondary endpoints from pivotal and additional trials of adalimumab in patients with
rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis (Furst et al 2003; Weinblatt et al 2003; Burmester et al 2004,
2005; Keystone et al 2004; van de Putte et al 2004; Breedveld et al 2005, 2006; Mease et al 2005, 2005a, 2005b; van der Heijde et al
2006)
Trial Name Treatment
a N Study Primary Secondary
Duration Endpoint(s) Endpoints
Rheumatoid Arthritis
ARMADA Adalimumab (20 mg,  69, 67, 73 24 wk ACR20: 48%, 67%, 66% ACR50: 32%, 55%, 43% vs
(Weinblatt et al 40 mg, 80 mg)   vs 15% 8%
2003) + MTX ACR70: 10%, 27%, 19% vs
10%
Placebo + MTX 62 HAQ: –0.54, –0.62, –0.59
vs –0.27
DE019 Adalimumab (40 mg 207, 212 52 wk ∆TSS: 0.1, 0.8 vs 2.7 ACR20: 59%, 55% vs 24%
(Keystone et al 2004) eow, 20 mg weekly) ACR20 at Week 24: 63%, ACR50: 42%, 38% vs 10%
+ MTX 61% vs 30% ACR70: 23%, 21% vs 5%
Placebo + MTX 200 ∆HAQ: –0.59, –0.61
vs –0.25
DE011 Adalimumab (20 mg 106, 112, 26 wk ACR20: 36%, 39%, 46%, ACR50: 19%, 21%, 22%, 35% vs
(van de Putte et al eow, 20 mg weekly, 113, 103 53% vs 19% 8%
2004) 40 mg, 40 mg weekly) 110 ACR70: 9%, 10%, 12%, 18% vs
Placebo  2%
Moderate EULAR response:
42%, 48%, 56%, 63% vs 26%
Good EULAR response: 7%,
10%, 9%, 14% vs 4%∆HAQ:
–0.29, –0.39, –0.38, –0.49 vs
–0.07
STAR Adalimumab + 318 24 wk AEs: no statistically ACR20: 53% vs 35%
(Furst et al 2003) DMARDs  significant differences ACR50: 29% vs 11%
Placebo + DMARDs 318 between adalimumab and ACR70: 15% vs 4%
placebo group in serious
AEs; severe or life-
threatening AEs; AEs leading
to withdrawal; rates of
infections or serious
infections
ReAct Adalimumab 6235 12 wk 12 Weeks 52 Weeks
(Burmester et al 1251 52 wk ACR20, 50, 70: 66%, 28%, ACR20, 50, 70: 67%, 45%, 24%
2004, 2005; 17% Moderate EULAR response:
Burmester pers Moderate EULAR response: 82%
comm. 2006) 81% Good EULAR response:
Good EULAR response: 38%
32%∆DAS28: –2.1 ∆DAS28: –2.3
DAS28 ≤2.6: 20% DAS28 ≤2.6: 35%
∆HAQ: –0.52 ∆HAQ: –0.57
Note: 
aThe dose of adalimumab is 40 mg eow unless specified otherwise.
Abbreviations: ACR, American College of Rheumatology; ADEPT, Adalimumab Effectiveness in Psoriatic Arthritis Trial; AE, adverse event; ARMADA, Anti-TNF
Research Study Program of the Monoclonal Antibody Adalimumab in Rheumatoid Arthritis; ASAS, ASessment in Ankylosing Spondylitis International Working Group
Improvement Criteria; ATLAS, Adalimumab Trial Evaluating Long-term Efficacy and Safety for Ankylosing Spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease
Activity Index; DAS28, Disease Activity Score 28; DMARDs, disease-modifying antirheumatic drugs; EULAR, European League Against Rheumatism; eow, every other
week; HAQ, Health Assessment Questionnaire; mTSS, modified Total Sharp Score; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; PGA, Physician’s Global
Assessment; ReAct, Research in Active Rheumatoid Arthritis Trial; STAR, Safety Trial of Adalimumab in Rheumatoid Arthritis; TSS, total Sharp score.
on the efficacy and safety of adalimumab, which was assessed
in 5 randomized, double-blind, placebo-controlled pivotal
trials in patients aged 18 years or older with active RA
diagnosed according to American College of Rheumatology
(ACR) criteria (Table 2). Adalimumab was administered
sc in combination with MTX (12.5–25mg), with other
disease-modifying antirheumatic drugs (DMARDs), or as
monotherapy (Humira PI 2005).Therapeutics and Clinical Risk Management 2007:3(1) 137
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Adalimumab plus methotrexate
The ARMADA (Anti-TNF Research Study Program of the
Monoclonal Antibody Adalimumab) trial evaluated 271
patients with active RA who had failed therapy with 1 to 4
DMARDs and had an inadequate response to MTX. Patients
received MTX plus adalimumab 20 mg, 40 mg, or 80 mg or
MTX plus placebo every other week (eow) for 24 weeks.
Patients receiving adalimumab plus MTX experienced
significant improvement in disease activity compared with
those receiving placebo plus MTX (Table 2). Responses
were rapid, with the greatest proportion of adalimumab-
treated patients achieving an ACR20 response at the first
scheduled visit (Week 1). Statistically greater improvements
in the Health Assessment Questionnaire Disability Index
(HAQ DI), in health-related quality-of-life measures (QOL)
(eg, Short Form-36 Health Survey [SF-36] and Functional
Assessment of Chronic Illness Therapy fatigue [FACIT-F]
scores), and in concentrations of acute-phase reactants (eg,
C-reactive protein) were observed for each adalimumab dose
plus MTX group (Weinblatt et al 2003). Results of extension
studies showed that clinical efficacy was sustained through
5 years with 76%, 64%, and 39% of patients achieving
ACR20, 50, 70 responses, respectively; 52% achieving
clinical remission; and 28% having no physical limitations
(Weinblatt et al 2004, 2005). In addition, most patients were
able to reduce corticosteroid and/or MTX dose without
adversely affecting long-term efficacy (Weinblatt et al 2005).
DE019, a 52-week, randomized, double-blind study,
investigated the ability of adalimumab to reduce disease
activity and inhibit radiographic progression in 619 RA
patients with active disease despite MTX therapy. Patients
received adalimumab 40 mg eow, adalimumab 20 mg
weekly, or placebo plus concomitant MTX. At Week 52,
there was statistically significantly less radiographic
Table 2 (Continued)
Trial Name Treatment
a N Study Primary Secondary
Duration Endpoint(s) Endpoints
Early Rheumatoid Arthritis
PREMIER Adalimumab + MTX  268 2 y ACR50 at 1 year: 62%, 41%, At Year 2: 
(Breedveld et al Adalimumab 274 vs 46% ACR20: 69%, 49% vs 56%
2005, 2006) MTX 257 ∆TSS at 1 year: 1.3, 3.0, ACR50: 59%, 37% vs 43%
vs 5.7  ACR70: 47%, 28% vs 28%
ACR90: 27%, 9% vs 13%
∆TSS: 1.9, 5.5 vs 10.4
DAS28 <2.6: 49%, 25% vs
25%
ACR70 maintained ≥6 months:
49%, 25% vs 27%
Psoriatic Arthritis
ADEPT Adalimumab 151 24  weeks ACR20  at  Week 12: 58% At Week 24:
(Mease et al 2005, Placebo 162 vs 14% ACR20: 57% vs 15%
2005a, 2005b) ∆mTSS at Week 24: –0.2 ACR50: 39% vs 6%
vs 1.0 ACR70: 23% vs 1%
PASI 50: 75% vs 12% 
PASI 75: 59% vs 1%
PASI 90: 42% vs 0%
PGA clear or almost clear:
71% vs 12%
∆HAQ: –0.4 vs –0.1
Ankylosing Spondylitis
ATLAS Adalimumab 208 12 weeks ASAS20: 58% vs 21% BASDAI 50: 45% vs 16%
(van der Heijde Placebo 107 ASAS40: 41% vs 14%
et al 2006) ASAS 5/6: 49% vs 13%
Partial remission: 21% vs 4%
Note: 
aThe dose of adalimumab is 40 mg eow unless specified otherwise.
Abbreviations: ACR, American College of Rheumatology; ADEPT, Adalimumab Effectiveness in Psoriatic Arthritis Trial; AE, adverse event; ARMADA, Anti-TNF
Research Study Program of the Monoclonal Antibody Adalimumab in Rheumatoid Arthritis; ASAS, ASessment in Ankylosing Spondylitis International Working Group
Improvement Criteria; ATLAS, Adalimumab Trial Evaluating Long-term Efficacy and Safety for Ankylosing Spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease
Activity Index; DAS28, Disease Activity Score 28; DMARDs, disease-modifying antirheumatic drugs; EULAR, European League Against Rheumatism; eow, every other
week; HAQ, Health Assessment Questionnaire; mTSS, modified Total Sharp Score; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; PGA, Physician’s Global
Assessment; ReAct, Research in Active Rheumatoid Arthritis Trial; STAR, Safety Trial of Adalimumab in Rheumatoid Arthritis; TSS, total Sharp score.Therapuetics and Clinical Risk Management 2007:3(1) 138
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progression, as measured by the change in total Sharp score
(TSS), in patients receiving adalimumab 40 mg eow plus
MTX versus the placebo group (mean change 0.1 vs 2.7,
respectively); moreover, 72% of adalimumab plus MTX-
treated patients had no radiographic progression from
baseline. QOL and functional improvement, as measured
by the SF-36 and HAQ DI, also were significantly improved
in the combination group versus placebo (Keystone et al
2004). Results from an open-label extension (OLE) of this
study showed that at 3 years 61% of patients had no
radiographic disease progression. In addition, significant
clinical responses were sustained with 58%, 42%, and 23%
of patients maintaining their ACR20, 50, and 70 responses,
respectively. Importantly, placebo-treated patients who had
significant disease progression at 52 weeks during the
randomized controlled trial experienced inhibition of
radiographic progression and improved clinical responses
when treated with adalimumab during the OLE (Keystone
et al 2004, 2004b, 2004c).
The results of ARMADA and DE019 confirm other
studies showing that TNF antagonists in combination with
MTX are more effective in the relief of signs and symptoms
of RA and in inhibiting radiographic progression than MTX
monotherapy, even in patients with long-standing disease.
Adalimumab plus traditional DMARDs
To establish the safety and effectiveness of adalimumab in
a broad RA population in real-life clinical practice, the open-
label Research in Active RA (ReAct) trial was conducted.
In this study, 6610 RA patients (the largest cohort of RA
patients to be treated with a TNF antagonist) with active
disease received adalimumab 40 mg eow in addition to their
current standard DMARD for 12 weeks, providing valuable
information on the drug’s performance in patients treated
with various DMARDs and with previous biologic
experience. At Week 12, 69% of patients achieved an ACR20
response and 83% achieved a moderate European League
Against Rheumatism (EULAR) response (Table 2). These
response rates were maintained over time in patients who
continued adalimumab treatment for 52 weeks during an
extension phase (Burmester et al 2005). Improvements in
functional status as measured by the Disease Activity Score
in 28 joints and the HAQ DI were also clinically significant
and sustained over time. In patients who had received prior
biologic therapy, the ACR20 response rate (60%) was only
slightly lower than in patients who were naïve to biologic
therapy (70%). Moderate (84%) and good (35%) EULAR
response rates were higher in the patients who had not
received prior treatment with a biologic response modifier
compared with those patients who had received at least 1
biologic agent. Thus, even after treatment failure with a TNF
antagonist, a significant clinical response can be achieved
with a different agent (Burmester et al 2004, 2005).
The STAR (Safety Trial of Adalimumab in RA) trial
assessed the safety and efficacy of adalimumab in a
heterogeneous group of RA patients with persistent disease
activity despite concomitant DMARD therapy. In this
randomized, double-blind study, 636 RA patients receiving
0 to ≥3 DMARDs received placebo or adalimumab 40 mg
eow for 24 weeks while continuing their baseline DMARDs.
Patients treated with adalimumab achieved statistically
superior ACR20, 50, and 70 response rates at Week 24
compared with placebo-treated patients (Table 2). There
were no statistically significant differences between the
adalimumab and placebo groups in their respective rates of
adverse events (AEs), serious AEs, severe or life-threatening
AEs, or AEs leading to withdrawal. In addition, rates of
infections or serious infections did not vary among the
groups, demonstrating the safety of adalimumab in patients
receiving standard DMARDs (Furst et al 2003).
Monotherapy
Adalimumab monotherapy may be appropriate for patients
who have not achieved adequate disease control with MTX
because of poor efficacy or tolerability. DE011, a 26-week,
double-blind, placebo-controlled trial, evaluated the efficacy
and safety of adalimumab monotherapy in 544 RA patients
with severely active disease for whom previous DMARD
treatment had failed (3.7 DMARDs on average). Patients
were randomized to placebo or monotherapy with 20 mg or
40 mg of adalimumab eow or weekly. Significantly better
response rates were observed in patients treated with
adalimumab 20 mg or 40 mg eow or weekly than in those
treated with placebo after 26 weeks (Table 2). Moderate
EULAR response rates also were significantly greater with
adalimumab than with placebo. In addition, the 40 mg
weekly dose resulted in a slightly higher ACR response than
40 mg eow. Adalimumab monotherapy achieved significant,
rapid, and sustained improvements in disease activity and
improved physical function in patients with severe RA
refractory to DMARD treatment (van de Putte et al 2004).
Early rheumatoid arthritis
Recent studies suggest that early, aggressive combination
treatment of RA achieves superior long-term outcomes
(O’Dell 2002; Keystone, Furst, et al 2003; Keystone,Therapeutics and Clinical Risk Management 2007:3(1) 139
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Kavanaugh, et al 2003; Keystone, Haraoui, et al 2003;
Weinblatt et al 2003; Keystone 2005). The PREMIER study
was a 2-year, randomized, double-blind, active comparator-
controlled trial designed to compare the efficacy and safety
of adalimumab plus MTX versus adalimumab monotherapy
or MTX monotherapy in 799 MTX-naïve RA patients with
early (<3 years), aggressive disease (Breedveld et al 2006).
It was the first head-to-head study of a TNF antagonist plus
MTX vs the TNF antagonist alone and MTX alone. Patients
received adalimumab 40mg eow plus MTX, adalimumab
40mg eow monotherapy, or MTX monotherapy. For all
endpoints, combination therapy was superior to both MTX
and adalimumab monotherapy (Table 2). At Year 2, the
percentage of patients who exhibited an ACR50 response
was 59% with combination therapy, 43% with MTX alone,
and 37% with adalimumab monotherapy (Figure 2a).
Combination therapy also yielded superior ACR20, 70, and
90 response rates at 1 and 2 years. The differences in
radiographic progression for patients treated with
adalimumab versus MTX alone at Year 1 were even more
marked at the end of Year 2, with an accumulated TSS
change of 10.4 in the MTX monotherapy arm versus 5.5 in
the adalimumab monotherapy arm and 1.9 in the
combination arm. Although ACR responses were
comparable between the 2 monotherapy arms, there was
statistically less radiographic progression with adalimumab
monotherapy than with MTX monotherapy at Year 1 (3.0
vs 5.7) and Year 2 (5.5 vs 10.4) (Figure 2b). After 2 years of
treatment, twice as many patients receiving combination
therapy than receiving adalimumab or MTX monotherapy
achieved a major clinical response and had no radiographic
progression. These findings emphasize that clinical
assessment of signs and symptoms of RA may not fully
reflect therapeutic benefit (van der Heijde, Landewe, et al
2005). A radiographic subanalysis conducted to examine
whether the frequency or severity of radiographic
progression at 6 months or 2 years varies with the level of
ACR response demonstrated the following (Genovese et al
2005):
· Adalimumab plus MTX led to less frequent and less
severe disease progression than MTX at all levels of
clinical response.
· ACR score was a poor predictor of radiographic efficacy;
therefore, radiographic monitoring may be warranted in
patients regardless of their clinical response.
· Early TNF-antagonist therapy may be needed to prevent
joint damage in patients with early RA, including some
with a good clinical response to MTX monotherapy.
For MTX-naïve patients with rapidly progressive, early RA,
adalimumab plus MTX showed greater radiographic
efficacy than MTX monotherapy across the entire spectrum
of radiographic disease progression parameters; moreover,
combination therapy prevented nearly all severe
radiographic progression observed with MTX alone, as early
as 6 months (van der Heijde, Landewe, et al 2005).
Psoriatic arthritis
Psoriatic arthritis is a chronic, inflammatory arthritis
commonly associated with psoriasis. Overexpression of TNF
is believed to play a key role in the pathogenic mechanisms
linking psoriasis and arthritis (Mease 2005). As with clinical
studies in RA, trials in PsA have shown excellent clinical
results with the TNF antagonists, etanercept (Mease et al
2000, 2003), infliximab (Mease et al 2004; Antoni et al 2003;
Antoni, Kavanaugh, et al 2005; Antoni, Krueger, et al 2005),
and adalimumab (Mease et al 2005a, 2005b; Mease, Sharp,
et al 2005), in a variety of domains, including the joints,
QOL, function, and radiographic progression. These agents
have also demonstrated benefit in domains more unique to
PsA, such as the skin lesions of psoriasis, enthesitis, and
dactylitis, highlighting the similar pathogenesis of the
disease in the skin, the tendons, and the synovial membrane
(Mease and Antoni 2005).
The Adalimumab Effectiveness in Psoriatic Arthritis
Trial (ADEPT) evaluated the safety and efficacy of
adalimumab as monotherapy or in combination with MTX
in patients with moderately to severely active PsA who had
failed nonsteroidal anti-inflammatory drug (NSAID)
therapy. Patients (n=313) were stratified according to MTX
use (yes or no) and extent of psoriasis involvement (≥3%
or <3% of body surface) at baseline and were subsequently
randomized to receive adalimumab 40 mg or placebo eow
for 24 weeks. Significantly higher ACR and Psoriasis Area
and Severity Index (PASI) response rates were observed in
patients treated with adalimumab than in those treated with
placebo at all time points (Table 2). At Week 24, the
physician’s global assessment of psoriasis among patients
with ≥3% body surface area affected resulted in ratings of
the lesions as clear or almost clear in 71% of the 70
adalimumab-treated patients compared with only 12% of
the 70 placebo-treated patients. Significant inhibition of
structural changes on radiographs also was observed with
adalimumab treatment. The mean change in the modified
TSS in patients who had both baseline and Week 24
radiographs was –0.2 for patients receiving adalimumab
versus 1.0 for patients receiving placebo. AdalimumabTherapuetics and Clinical Risk Management 2007:3(1) 140
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Figure 2 Results from the PREMIER study. (a) American College of Rheumatology 50 response at Years 1 and 2. aP<0.001 for adalimumab plus methotrexate (MTX)
vs MTX alone and adalimumab plus MTX vs adalimumab alone. (b) Mean change from baseline in total Sharp scores (TSS) over time. aP<0.001 for adalimumab plus
MTX vs MTX alone and adalimumab alone. bP<0.001 for adalimumab plus MTX vs MTX alone and P=0.002 for adalimumab plus MTX vs adalimumab alone. cP<0.001
for adalimumab vs MTX alone. Copyright © 2006. Reproduced with permission from Breedveld FC, Weisman MH, Kavanaugh AF, et al; for the PREMIER investigators.
2006. The PREMIER Study: combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in methotrexate-naïve patients
with early, aggressive rheumatoid arthritis. Arthritis Rheum, 54:26-37.
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treatment also significantly improved disability (HAQ),
QOL (SF-36), and fatigue (FACIT) measures in patients with
moderately to severely active PsA (Mease et al 2005a).
Notably, observed improvement in the skin symptoms of
psoriatic disease was more dramatic with adalimumab than
with etanercept or infliximab (Mease et al 2000, 2004),
although the efficacy of these agents in PsA has not been
studied in a head-to-head trial.
In an ongoing OLE of this trial, all continuing patients
received adalimumab 40 mg eow. For patients initially
treated with adalimumab, ACR and PASI response rates
were maintained over 48 weeks of treatment (ACR20/50/
70; 61%/46%/31% [Figure 3a]) (PASI 50/75/90; 70%/58%/
46% [Figure 3b]). For patients previously receiving placebo
and newly receiving adalimumab, ACR20, 50, and 70
response rates were 54%, 37%, and 21%, respectively
(Figure 3a). Of 152 placebo- and 144 adalimumab-treated
patients who had radiographs at baseline and 24 weeks, 141
and 133, respectively, had radiographs taken at Week 48.
Mean change in modified TSS at Week 24 was maintained
to Week 48 in adalimumab-treated patients (Figure 3c)
(Mease et al 2005b; Mease, Sharp, et al 2005). A recent
ADEPT subanalysis assessing the correlation of skin and
joint responses showed that 84% of ACR50 responders and
94% of ACR70 responders also achieved a PASI 75 response
(Ritchlin et al 2006).
Ankylosing spondylitis
Ankylosing spondylitis is a chronic inflammatory disease
primarily affecting the sacroiliac joints and spine. The
rationale for treating AS with a TNF antagonist is based on
the observation that large amounts of TNF are expressed at
the site of inflammation in patients with this disease (Braun
et al 1995). Recent studies have demonstrated significant
efficacy of TNF antagonist therapy for the treatment of AS
(Gorman et al 2002; Brandt et al 2003; Braun et al 2002,
2003; van der Heijde, Dijkmans, et al 2005), and
adalimumab received expanded approval for the treatment
of severe, active AS from the European Commission in June
2006.
Adalimumab was evaluated in a 2:1, randomized,
double-blind, multicenter study, ATLAS (Adalimumab Trial
Evaluating Long-term Efficacy and Safety in Ankylosing
Spondylitis), to assess its efficacy and safety in patients with
AS (Table 2). Assessment in AS (ASAS) International
Working Group criteria were significantly improved after 2
weeks of adalimumab therapy; 58% of adalimumab-treated
patients achieved an ASAS20 response compared with 21%
of placebo-treated patients (Figure 4a). In addition,
significantly more adalimumab-treated patients had at least
a 50% improvement in the Bath AS Disease Activity Index
(BASDAI) score at Week 12 compared with the placebo
group (45% vs 16%, respectively). Patients treated with
adalimumab also achieved significantly higher ASAS5/6,
ASAS40, and partial remission responses at Weeks 12 and
24 compared with placebo-treated patients (Figure 4b).
Adalimumab significantly improved BASFI (Bath
Ankylosing Spondylitis Functional Index) scores; at Week
12, adalimumab-treated patients had a statistically
significantly greater improvement in BASFI scores (–35.8)
compared with placebo-treated patients (–8.0) and a
sustained response at Week 24 (–37.7 vs –8.5). Adalimumab-
treated patients also experienced a significant reduction in
enthesis pain, as indicated by both the Maastricht
Ankylosing Spondylitis Enthesitis Score (MASES) and the
enthesis question on the BASDAI. At Week 12,
adalimumab-treated patients had a statistically significantly
greater improvement in MASES (–2.68) compared with
placebo-treated patients (–1.28) and a sustained response
at Week 24 (–3.21 vs –1.55). Uniquely in this study, patients
with radiographic evidence of total spinal ankylosis were
allowed to enroll. Of these patients, 50% (3/6) treated with
adalimumab achieved an ASAS20 response at Week 12
compared with 0% (0/5) of placebo patients. At Week 24,
66.7% (4/6) of the adalimumab patients had an ASAS20
response compared with 0% (0/5) of the placebo patients
(van der Heijde et al 2006).
Safety
Adalimumab has been prescribed to more than 110 000
patients worldwide (Schiff et al 2006). The safety profile
has been extensively studied in randomized and long-term
OLE clinical trials. Schiff and colleagues (2006) evaluated
two sources of data to describe the incidences of serious
adverse events (SAEs) of interest with adalimumab in RA
patients: as of April 15, 2005, the RA clinical trial database
included 10 050 patients, representing 12 506 patient-years
(PY) of adalimumab exposure and as of June 30, 2005, an
estimated 78 522 PY of adalimumab exposure were included
from the US postmarketing period. Based on these 2 sources
of data, adalimumab has been shown to be generally safe
and well-tolerated in patients with RA. The rates of adverse
events were low and stable over time (Schiff et al 2006).
Table  3  lists  AEs  reported  by  ≥5%  of  adalimumab-
treated patients during placebo-controlled periods of RA
studies (Humira PI 2005) (Table 3). Injection site reactionsTherapuetics and Clinical Risk Management 2007:3(1) 142
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Figure 3 Results from ADEPT (Adalimumab Effectiveness in Psoriatic Arthritis Trial). (a) Percentage of patients with psoriatic arthritis who achieved a 20%, 50%, and
70% improvement in American College of Rheumatology (ACR) response criteria at Week 24 and Week 48. aP<0.001 placebo vs adalimumab at Week 24, adjusted for
baseline methotrexate use and extent of psoriasis at baseline. bPlacebo patients received adalimumab after Week 24. Patients who prematurely discontinued prior to
receiving adalimumab are not included in this analysis. (b) Percentages of patients with psoriatic arthritis and ≥3% body surface area psoriasis involvement at baseline
who achieved a 50%, 75%, and 90% improvement in Psoriasis Area and Severity Index (PASI) response criteria at Week 24 and Week 48. aP<0.001 placebo vs
adalimumab at Week 24, adjusted for baseline methotrexate use and extent of psoriasis at baseline. bPlacebo patients received adalimumab after Week 24. Patients
who prematurely discontinued prior to receiving adalimumab are not included in this analysis. (c) Changes in modified total Sharp score (mTSS) at Weeks 24 and 48.
aP<0.001 placebo vs adalimumab using a ranked analysis of covariance (Mease at al 2005, 2005a, 2005b).
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are the most common AE associated with adalimumab
treatment across RA trials (20.3% for adalimumab vs 13.8%
for placebo). Most of these reactions were mild to moderate
and did not recur (Wells et al 2003). The adverse event
profile and overall safety of adalimumab in PsA and AS
patients are similar to that reported in patients with RA
(Weinblatt et al 2003; Keystone et al 2004; van de Putte et
al 2004; Mease et al 2005a, 2005b; van der Heijde et al
2006).
Since the introduction of TNF antagonists, which affect
host defenses by modulating cellular immune responses,
there has been concern about an increased risk of serious
infections among TNF-antagonist–treated patients. Recent
safety analyses of adalimumab in global clinical trials and
US postmarketing surveillance of RA patients indicated that
rates of serious infections were similar to those reported
with DMARDs and other TNF antagonists across RA trials
and did not increase over time (Schiff et al 2003, 2006).
Across 4 pivotal trials for RA (ARMADA, DE011, DE019,
and STAR) infection rates were similar to placebo, at
approximately 1.0/PY (Humira PI 2005). The most
frequently reported infections were upper respiratory tract
infections, rhinitis, bronchitis, and urinary tract infections
(Lee and Kavanaugh 2005).Therapeutics and Clinical Risk Management 2007:3(1) 143
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There is an increased risk of tuberculosis (TB) in the
context of anti-TNF therapy, which has led to the
recommendation for screening for TB prior to initiation of
therapy. From December 31, 2002, to June 30, 2005,
postmarketing surveillance has noted 17 cases of TB among
the 78 522 PY of adalimumab exposure (0.2/100 PY) (Schiff
et al 2006). These data are consistent with those for other
TNF antagonists. In the adalimumab RA clinical trials, prior
to the initiation of routine TB screening, there were 7 cases
of TB in Europe (1.3/100 PY). The introduction of routine
TB screening in clinical trials has decreased the rate of TB
by 75% (0.33/100 PY) (Schiff et al 2006).
Opportunistic infections have been reported with the use
of all 3 TNF antagonists (Keystone 2005). These infections
include histoplasmosis, listeriosis, pulmonary aspergillosis,
and Pneumocystis carinii pneumonia. In patients receiving
adalimumab, opportunistic infections are infrequent and
involve a variety of organisms (Schiff et al 2006).
Other safety issues include autoimmune disease,
demyelination disorders, and malignancies, particularly
lymphoma (Lee and Kavanaugh 2005). Autoantibodies to
antinuclear antigen and double-stranded DNA develop in
approximately 3% to 12% of adalimumab-treated patients.
The clinical implications of these antibodies remain to be
defined, as progression to lupus-like illness appears to be
uncommon. After 12 506 PY of adalimumab exposure, only
13 cases of systemic lupus erythematosus and lupuslike
syndromes have been reported in the RA clinical trials
(Schiff et al 2006).
Rare cases of neurologic AEs have been reported in
association with adalimumab and other TNF antagonists.
Ten cases of demyelinating diseases were observed among
RA patients after 12 506 PY of exposure (0.08/100 PY); 6
were multiple sclerosis (MS) cases (Schiff et al 2006).
Patients with MS have a statistically significantly higher
coexistence of RA and psoriasis than matched controls,
suggesting that patients with these conditions may innately
be at increased risk of MS as compared with the general
population (Heinzlef et al 2000; Magnano et al 2004). The
true impact of TNF antagonists on the development of this
disorder is unknown (Magnano et al 2004; Lee and
Kavanaugh 2005).
There is some speculation that lymphomas may be
associated with the use of TNF antagonists (Geborek et al
2005). Among adalimumab recipients, 15 cases of
lymphoma were observed (0.12/100 PY) after 12 506 PY
of exposure in RA clinical trials (Schiff et al 2006). These
incidence rates do not appear, at this time, to exceed those
reported in the RA population prior to the availability of
TNF inhibitors. Reports in the literature suggest that RA
patients are at increased risk for lymphoma compared with
the general population, which may be further increased in
patients with highly active disease (Isomaki et al 1978). Most
patients in adalimumab clinical trials had moderately to
severely active RA at trial entry, increasing their risk for
lymphoma. The standardized incidence ratio of 3.19 for
lymphoma in adalimumab-treated patients is consistent with
that expected in RA patients naïve to TNF antagonists. Rates
of lymphoma and of the previously mentioned AEs have
remained stable over time (Table 4) (Schiff et al 2006). For
PsA and AS trials, rates of lymphoma were 0.41 and 0.24/
100 PY, respectively (Burmester et al 2006). Most analyses
to date have found no association between anti-TNF therapy
and non-lymphomatous cancers. However, results from a
recent meta-analysis of 9 randomized clinical trials of
infliximab and adalimumab suggest that treatment with TNF
inhibitors may be associated with an increased risk for
Table 3 Adverse events reported by ≥5% of patients treated
with adalimumab during placebo-controlled periods of
rheumatoid arthritis studies (Humira PI 2005)
Adverse event Adalimumab Placebo
40 mg eow (n=690)
(n=705) (%) (%)
Respiratory
Upper respiratory infection 17 13
Sinusitis 11 9
Flu syndrome 7 6
Gastrointestinal
Nausea 9 8
Abdominal pain 7 4
Laboratory tests
a
Laboratory test abnormal 8 7
Hypercholesterolemia 6 4
Hyperlipidemia 7 5
Hematuria 5 4
Alkaline phosphatase 5 3
increased
Other
Injection site pain 12 12
Headache 12 8
Rash 12 6
Accidental injury 10 8
Injection site reactionb 81
Back pain 6 4
Urinary tract infection 8 5
Hypertension 5 3
Note: aLaboratory test abnormalities were reported as adverse events in
European trials; 
bDoes not include erythema and/or itching, hemorrhage, pain, or
swelling.
Abbreviations: eow, every other week.Therapuetics and Clinical Risk Management 2007:3(1) 144
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Figure 4 Results from ATLAS (Adalimumab Trial Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis). (a) Proportion of patients who achieved a 20%
improvement response over time according to the criteria of the ASssessment in Ankylosing Spondylitis (ASAS) Working Group. aP<0.001 vs placebo based on an
intention-to-treat analysis using nonresponder imputation. (b) ASAS 5/6 criteria response, ASAS40 response, and partial remission. aP<0.001 vs placebo based on an
intention-to-treat analysis using nonresponder imputation. Copyright (c) 2006. Reproduced with permission from van der Heijde D, Kivitz A, Schiff MH, et al; the
Adalimumab Trial Evaluating Long-term Efficacy and Safety in Ankylosing Spondylitis Study Group. 2006. Efficacy and safety of adalimumab in patients with ankylosing
spondylitis: results of a randomized, placebo-controlled trial (ATLAS). Arthritis Rheum, 54:2136-46.
0
10
20
30
40
50
60
70
02468 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4
Week
P
a
t
i
e
n
t
s
 
(
%
)
Placebo Adalimumab
a
a
aa
a a a
13.1 14
3.7
12.1 14
5.6
48.6
40.9
20.7
44.7
39.4
22.1
0
10
20
30
40
50
60
ASAS 5/6
Response
ASAS40
Response
Partial
Remission
ASAS 5/6
Response
ASAS40
Response
Partial
Remission
P
a
t
i
e
n
t
s
 
(
%
)
Placebo Adalimumab
Week 12 Week 24
a
a
a
a
a
a
Figure 4a
Figure 4bTherapeutics and Clinical Risk Management 2007:3(1) 145
Adalimumab in the treatment of arthritis
serious infections and malignancies (Bongartz et al 2006).
In contrast, a large population-based study using data from
the Swedish nationwide cancer and census registers did not
find an increased risk of solid malignancies in RA patients
treated with TNF antagonists (Askling et al 2005). Further
evaluations are needed to assess the true risks for these
important adverse events with anti-TNF therapy.
Patient-focused perspectives
Several studies have examined the effect of adalimumab
therapy on health-related quality of life (HRQOL) and
functional status. In both concomitant therapy and
monotherapy trials, adalimumab was associated with
significantly greater improvements from baseline in HRQOL
measures than placebo (Weinblatt et al 2003, 2005; Keystone
et al 2004; van de Putte et al 2004; Breedveld et al 2005,
2006; Mease et al 2005; Burmester pers comm. 2006).
DE019, ARMADA, and STAR trials demonstrated
significantly greater improvements in FACIT-F scores
(Strand, Weisman, et al 2003); SF-36 domain scores for
Physical Functioning, Bodily Pain, and Vitality; and SF-36
Physical and Mental Component Summary (PCS, MCS)
Scores (with adalimumab 40 mg eow than with placebo (in
combination with MTX or standard antirheumatic therapy)
after 24 weeks (Strand, Chartash, et al 2003). Quality-
adjusted life-years gained per year of treatment were 0.10,
0.15 and 0.07, respectively, with adalimumab 40 mg eow
(in combination with MTX or standard antirheumatic
therapy) (Strand, Weisman, et al 2003). In the ADEPT trial,
disability (as measured by the HAQ DI) improved
significantly among PsA patients receiving adalimumab
compared with those receiving placebo through Week 24
(–0.4 ± 0.5 in the adalimumab group vs –0.1 ± 0.5 in the
placebo group at Week 12). Statistically significant
improvements in SF-36 PCS scores, FACIT-F scores, and
Dermatologic Life-Quality Index (DLQI) scores were also
observed at Week 24 in patients receiving adalimumab
(Mease et al 2005a).
Conclusions
Tumor necrosis factor has been implicated in a number of
arthritic disease states, including RA (Saxne et al 1988),
PsA (Partsch et al 1997; Ritchlin et al 1998), and AS (Braun
et al 1995). Inhibition of TNF activity by adalimumab has
been shown to significantly improve signs and symptoms,
function, and QOL; induce remission; and reduce
objectively measured damage in patients with these
conditions (Weinblatt et al 2003; Keystone et al 2004a,
2004b; 2004c; van de Putte et al 2004; Mease et al 2005a,
2005b; van der Heijde et al 2006). Adalimumab has a rapid
onset of action and sustained efficacy with long-term
treatment and is well-tolerated, with few patients
discontinuing treatment because of adverse events (Humira
PI 2005).
Place of adalimumab in therapy
Adalimumab in combination with MTX or standard
antirheumatic therapies, or as monotherapy, is effective in
the treatment of adults with active RA who have had an
inadequate response to DMARDs. Adalimumab is also
effective in the treatment of patients with moderately to
severely active PsA, improving both joint and skin
manifestations of the disease as well as disability due to
joint damage (Mease et al 2005a). In the ATLAS trial,
adalimumab significantly reduced the signs and symptoms
of active AS and established a sustained clinical response
in patients who had an inadequate response or intolerance
to NSAID therapy (van der Heijde et al 2006). ACR
treatment guidelines recommend the use of biologic agents
in patients who have a contraindication to MTX therapy or
who have not achieved adequate disease control with MTX
because of poor efficacy or tolerability. Unlike traditional
DMARDs, patients receiving adalimumab do not require
routine laboratory monitoring for adverse effects. As with
the other TNF antagonists, patients must be screened for
infections prior to commencing therapy (TB, in particular)
and monitored for the presence of infection during therapy.
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